Lipids are the fatty molecules that make up cellular membranes, creating a protective barrier that regulates what enters and ...

Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

SHANGHAI, April 30, 2025 /PRNewswire/ -- Mabwell (688062), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in ...

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China ...

EpiBiologics, a leader in tissue-selective extracellular protein degradation, today presented the first preclinical data on its EpiTAC bispecific antibody degrader of c-Met, a potential first-in-class ...

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the ...

ZW171 exhibits strong anti-tumor activity in patient derived xenograft (PDX) models of NSCLC and pancreatic cancer, and in ex-vivo patient-derived ovarian cancer organoids with endogenous ...

With fully integrated multi-functional platform, Akeso is internally working on a ... Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and ...

Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special purpose acquisition company (SPAC) model to hop onto the Nasdaq. | Market ...